At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALT Altimmune, Inc.
Market Closed 10-09 16:00:00 EDT
2.61
+0.01
+0.38%
盘后2.64
+0.03+1.12%
19:46 EDT
High2.64Low2.57Vol2.68M
Open2.60D1 Closing2.60Amplitude2.69%
Mkt Cap506.34MTradable Cap428.04MTotal Shares194.00M
T/O6.99MT/O Rate1.63%Tradable Shares164.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Altimmune Files Form 3 for Principal Accounting Officer Richard Thomas Menziuso
Reuters  ·  10-03
Altimmune Files Form 3 for Principal Accounting Officer Richard Thomas Menziuso
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
GlobeNewswire  ·  09-30
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
Altimmune Names Richard Menziuso Principal Accounting Officer, Global Controller VP
Reuters  ·  09-29
Altimmune Names Richard Menziuso Principal Accounting Officer, Global Controller VP
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
GlobeNewswire  ·  09-14
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
GlobeNewswire  ·  09-08
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
GlobeNewswire  ·  08-26
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
ALT Co. to Host Non-Deal Roadshow for Q2 2026 Results in Seoul
TIPRANKS  ·  08-20
ALT Co. to Host Non-Deal Roadshow for Q2 2026 Results in Seoul
NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer
Reuters  ·  08-15
NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer
Altimmune CEO Jerome Benedict Durso Acquires USD 44,250 in Common Shares
Reuters  ·  08-14
Altimmune CEO Jerome Benedict Durso Acquires USD 44,250 in Common Shares
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)
TIPRANKS  ·  08-13
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)
Analysts Offer Insights on Healthcare Companies: Oscar Health (OSCR), Altimmune (ALT) and HCA Healthcare (HCA)
TIPRANKS  ·  08-13
Analysts Offer Insights on Healthcare Companies: Oscar Health (OSCR), Altimmune (ALT) and HCA Healthcare (HCA)
U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte
Reuters  ·  08-13
U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte
Altimmune Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-12
Altimmune Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Altimmune Rises on Smaller-than-Expected Quarterly Loss
Reuters  ·  08-12
Altimmune Rises on Smaller-than-Expected Quarterly Loss
Altimmune Posts Smaller-than-Expected Q2 Net Loss Per Share
Reuters  ·  08-12
Altimmune Posts Smaller-than-Expected Q2 Net Loss Per Share
Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate
Benzinga Earnings  ·  08-12
Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  08-11
Calendar of U.S. Earnings Expected in the Week Ahead
Altimmune Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview
Reuters  ·  08-10
Altimmune Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview
Bitcoin holds a resistance break as gold surges and ALT risk builds
Kitco  ·  08-06
Bitcoin holds a resistance break as gold surges and ALT risk builds
Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH
MT Newswires Live  ·  08-03
Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH

Introduction

Company Name.
Altimmune, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Issue price:
--